Yahoo Finance

Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is positive on the launch of Journavx, which is seeing “broad based support even from political foes”, the analyst tells investors in a research note. There should be demand for Journavx as an alternative to opioids, even if it takes some time, Truist adds.

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.

• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on VRTX:

• Vertex Pharmaceuticals price target raised to $407 from $402 at RBC Capital

• Vertex Pharmaceuticals’ Journavx: Strategic Market Adoption and Growth Outlook

• Vertex Pharmaceuticals price target raised to $459 from $450 at Morgan Stanley

• Vertex Pharmaceuticals: Mixed Financial Performance and Future Prospects Lead to Hold Rating

• Vertex Pharmaceuticals: Hold Rating Due to Mixed Outlook and Generic Competition Risks